

SUPPLEMENTARY INFORMATION: On June 15, 1984, OMB delegated to the Board authority under the Paperwork Reduction Act (PRA) to approve and assign OMB control numbers to collections of information conducted or sponsored by the Board. Board-approved collections of information are incorporated into the official OMB inventory of currently approved collections of information. The OMB inventory, as well as copies of the PRA Submission, supporting statements (which contain more detailed information about the information collections and burden estimates than this notice), and approved collection of information instrument(s) are available at <https://www.reginfo.gov/public/do/PRAMain>. These documents are also available on the Federal Reserve Board's public website at <https://www.federalreserve.gov/apps/reportingforms/review> or may be requested from the agency clearance officer, whose name appears above. On the page displayed at the link above, you can find the supporting information by referencing the collection identifier, FR 28.

Final Approval Under OMB Delegated Authority of the Extension for Three Years, With Revision, of the Following Information Collections

Collection title: Applications for Employment with the Board of Governors of the Federal Reserve System.

Collection identifier: FR 28.

OMB control number: 7100–0181.

General description of collection: The FR 28 consists of the following information collections:

The Application for Employment (FR 28a), which collects information to determine the qualifications of applicants for employment with the Board (such as education and training, employment records, and other general background information since the time the applicant left high school), the Applicant's Voluntary Self-Identification (FR 28s), which is an optional form that collects information on the applicant's sex, race, and ethnicity, the Research Assistant Application (FR 28i), which collects contact information, information on a Research Assistant (RA) applicant's level of interest in various economic topics and experience in different data analytics/programs, and application documentation (including resume, cover letter, transcripts, and letter(s) of recommendation), the Pre-Hire Conflict of Interest Screening Form (FR 28c), which collects information from external applicants after they have been

selected for an interview at the Board regarding certain financial interests that could pose a conflict of interest based on the Board's supplemental ethics regulations and/or the duties of the position for which they are applying, and the Reference Check Form (FR 28r), which captures information from professional references when the Board conducts reference checks for external applicants who have received a verbal offer of employment.

Frequency: Event-generated.

Respondents: Individuals seeking employment with the Board.

Total estimated number of respondents: FR 28a (LinkedIn), 14,076; FR 28a (Resume Parsing), 18,098; FR 28a (Manual Application), 4,021; FR 28a (Use Last Application), 4,021; FR 28a (Interview Selection), 1,129; FR 28a (PDF), 238; FR 28s, 40,216; FR 28i, 800; FR 28c, 1,547; and FR 28r, 273.

Estimated average hours per response: FR 28a (LinkedIn), 0.46; FR 28a (Resume Parsing), 0.44; FR 28a (Manual Application), 0.69; FR 28a (Use Last Application), 0.26; FR 28a (Interview Selection), 0.71; FR 28a (PDF), 1.69; FR 28s, 0.02; FR 28i, 0.91; FR 28c, 0.62; and FR 28r, 0.34.

Total estimated change in burden: (1,950).

Total estimated annual burden hours: 22,045.

Current actions: On July 9, 2026, the Board published a notice in the **Federal Register** (91 FR 42441) requesting public comment for 60 days on the extension, with revision, of the FR 28. The Board proposed to revise the FR 28 by changing the collection platform of the FR 28a and FR 28s from Taleo to Workday, which will allow for three new submission methods in the Workday system (applying through LinkedIn, applying with resume parsing, and applying with previous application); the FR 28c, which is currently sent out via email, will also transition into Workday. The platform change will result in several data field changes for the FR 28a to (1) align with the configuration of Workday as the Board's new applicant tracking system (ATS) and (2) remove fields that are no longer necessary. By Fall 2028, the FR 28i will also be transitioned from ServiceNow to Workday. Before the transition of the FR 28i into Workday, one additional data field will be added in order to link applicants between ServiceNow and Workday; once the FR 28i is also in Workday, the data field will be removed. There were no proposed changes to the FR 28r as part of this clearance. The comment period for this notice expired on September 8, 2026. The Board did not receive any

comments. The revisions will be implemented as proposed.

Board of Governors of the Federal Reserve System, October 2, 2026.

Erin M. Cayce,

Assistant Secretary of the Board.

[FR Doc. 2026–20478 Filed 10–5–26; 8:45 am]

BILLING CODE 6210–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2026–P–3632]

Determination PRALIDOXIME CHLORIDE (Autoinjector) (Pralidoxime Chloride) Solution, 600 Milligrams/2 Milliliters (300 Milligrams/Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA, Agency, or we) has determined that PRALIDOXIME CHLORIDE (AUTOINJECTOR) (pralidoxime chloride) solution, 600 milligrams (mg)/2 milliliters (mL) (300 mg/mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for pralidoxime chloride solution, 600 mg/2 mL (300 mg/mL), if all other legal and regulatory requirements are met.

FOR FURTHER INFORMATION CONTACT: Awo Archampong-Gray, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6243, Silver Spring, MD 20993–0002, 301–796–0110, Awo.Archampong-Gray@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355(j)) allows the submission of an ANDA to market a generic version of a previously approved drug product. To obtain approval, the ANDA applicant must show, among other things, that the generic drug product: (1) has the same active ingredient(s), dosage form, route of administration, strength, conditions of use, and (with certain exceptions) labeling as the listed drug, which is a version of the drug that was previously approved, and (2) is bioequivalent to the listed drug. ANDA applicants do not have to repeat the extensive clinical testing otherwise necessary to gain

approval of a new drug application (NDA).

Section 505(j)(7) of the FD&C Act requires FDA to publish a list of all approved drugs. FDA publishes this list as part of the “Approved Drug Products With Therapeutic Equivalence Evaluations,” which is known generally as the “Orange Book.” Under FDA regulations, drugs are removed from the list if the Agency withdraws or suspends approval of the drug’s NDA or ANDA for reasons of safety or effectiveness or if FDA determines that the listed drug was withdrawn from sale for reasons of safety or effectiveness (21 CFR 314.162).

A person may petition the Agency to determine, or the Agency may determine on its own initiative, whether a listed drug was withdrawn from sale for reasons of safety or effectiveness. This determination may be made at any time after the drug has been withdrawn from sale, but must be made prior to approving an ANDA that refers to the listed drug (§ 314.161 (21 CFR 314.161)). FDA may not approve an ANDA that does not refer to a listed drug.

PRALIDOXIME CHLORIDE (AUTOINJECTOR) (pralidoxime chloride) solution, 600 mg/2 mL (300 mg/mL), is the subject of NDA 018986, held by Meridian Medical Technologies, Inc., and initially approved on April 26, 1983. **PRALIDOXIME CHLORIDE (AUTOINJECTOR)** is indicated for intramuscular use as an adjunct to atropine in the treatment of poisoning by nerve agents having anticholinesterase activity.

PRALIDOXIME CHLORIDE (AUTOINJECTOR) (pralidoxime chloride) solution, 600 mg/2 mL (300 mg/mL), is currently listed in the “Discontinued Drug Product List” section of the Orange Book.

Premier Research International, LLC, submitted a citizen petition dated March 25, 2026 (Docket No. FDA–2026–P–3632), under 21 CFR 10.30, requesting that the Agency determine whether **PRALIDOXIME CHLORIDE (AUTOINJECTOR)** (pralidoxime chloride) solution, 600 mg/2 mL (300 mg/mL), has been voluntarily withdrawn for reasons of safety or effectiveness.

After considering the citizen petition and reviewing Agency records and based on the information we have at this time, FDA has determined under § 314.161 that **PRALIDOXIME CHLORIDE (AUTOINJECTOR)** (pralidoxime chloride) solution, 600 mg/2 mL (300 mg/mL), was not withdrawn for reasons of safety or effectiveness. The petitioner has identified no data or other information

suggesting that **PRALIDOXIME CHLORIDE (AUTOINJECTOR)** (pralidoxime chloride) solution, 600 mg/2 mL (300 mg/mL), was withdrawn for reasons of safety or effectiveness. We have carefully reviewed our files for records concerning the withdrawal of **PRALIDOXIME CHLORIDE (AUTOINJECTOR)** (pralidoxime chloride) solution, 600 mg/2 mL (300 mg/mL), from sale. We have also independently evaluated relevant literature and data for possible postmarketing adverse events. We have found no information that would indicate that this drug product was withdrawn from sale for reasons of safety or effectiveness.

Accordingly, the Agency will continue to list **PRALIDOXIME CHLORIDE (AUTOINJECTOR)** (pralidoxime chloride) solution, 600 mg/2 mL (300 mg/mL), in the “Discontinued Drug Product List” section of the Orange Book. The “Discontinued Drug Product List” delineates, among other items, drug products that have been discontinued from marketing for reasons other than safety or effectiveness. ANDAs that refer to this drug product may be approved by the Agency as long as they meet all other legal and regulatory requirements for the approval of ANDAs. If FDA determines that labeling for this drug product should be revised to meet current standards, the Agency will advise ANDA applicants to submit such labeling.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2026–20442 Filed 10–5–26; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2026–N–10429]

Design and Safety Considerations for Clinical Trials Involving Ibogaine Drug Products; Request for Information

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; request for information; establishment of a public docket.

SUMMARY: The Food and Drug Administration (FDA or the Agency) is describing the approaches it is considering for the design of early-phase clinical trials of ibogaine drug products and is opening a public docket to receive comments. The Department of

Health and Human Services (HHS) is funding clinical development of ibogaine, and the first federally supported trials are expected to study ibogaine in adults with opioid use disorder (OUD) and adults with post-traumatic stress disorder (PTSD). FDA is building on the guidance for industry entitled “Psychedelic Drugs: Considerations for Clinical Investigations” by seeking comments, data, and information from the public on protocol elements relevant to ibogaine development—including dose selection and escalation, care setting, safety monitoring, eligibility criteria, stopping rules, and safety oversight, in part, because the Federal Government is funding work in this area. FDA will consider all information provided in response to this Request for Information (RFI) to inform whether and how these specific elements should be considered in its review of Investigational New Drug Applications (INDs) involving ibogaine.

DATES: Submit either electronic or written comments, data, or information by November 20, 2026.

ADDRESSES: You may submit comments, data, and information as follows. Please note that late, untimely filed comments will not be considered. The <https://www.regulations.gov> electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of November 20, 2026. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are received on or before that date.

Electronic Submissions

Submit electronic comments in the following way:

- **Federal eRulemaking Portal:** <https://www.regulations.gov>. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to <https://www.regulations.gov> will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on <https://www.regulations.gov>.
- If you want to submit a comment with confidential information that you